Clarivate Plc (NYSE: CLVT) has agreed to sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million. Altaris, a firm specializing in healthcare investments, will pay $500 million in cash at closing, with an additional $25 million deferred until the completion of a transition services agreement and a $75 million seller note.
The transaction is anticipated to close by the end of the year, pending regulatory approvals. Post-sale, Clarivate will focus on its Academia & Government and Intellectual Property segments, which already leverage strong customer relationships and shared technology platforms.
The company plans to use the cash proceeds to reduce debt and enhance shareholder value. After the transaction closes, expected in the third quarter of 2026, the segment will be reported as discontinued operations.
Clarivate has reaffirmed its 2026 financial outlook, which includes the Life Sciences & Healthcare segment’s results for the full year.
Clarivate projects organic ACV growth of 2.0 percent–3.0 percent, recurring organic revenue growth of 0.75 percent–2.25 percent, and total revenue between $2.30 billion and $2.42 billion.
The company also anticipates adjusted EBITDA of $980 million–$1.04 billion and adjusted diluted EPS of $0.70–$0.80. Clarivate expects to incur a non-cash goodwill impairment charge of $225–250 million, which will not affect its full-year guidance.
Matti Shem Tov, CEO of Clarivate, stated, “We are pleased to have reached this agreement, which is well-aligned with Clarivate’s four-pillared Value Creation Plan to optimize our business model, improve our sales execution, accelerate innovation and rationalize our portfolio, all with the goal of unlocking shareholder value.”
